Furthermore, inhibiting RAC1 can restore sensitivity to targeted therapy trastuzumab in breast cancer, suggesting that RAC1 inhibition could be an additional target for therapy in CRC [148]. This evidence concerns the gene RAC1 and colorectal carcinoma.